Clinical
RSSArticles
-
2016 USPSTF Update: Recommendations for and Effectiveness of Screening Mammography
The U.S. Preventive Services Task Force recently released updates to the 2009 recommendations on breast cancer screening. Additional studies published since the last review strengthen the conclusion that mammography screening results in a reduction in the risk of death from breast cancer.
-
Clinical Briefs
In this section: another reason to take vitamin D supplements; polishing physical exam skills; and comparing the relationship between uric acid, fructose, and hypertension.
-
Elbasvir and Grazoprevir Tablets (Zepatier)
The FDA has approved another oral interferon-free regimen for the treatment of chronic hepatitis C (HCV) genotypes 1 and 4.
-
Should Postmenopausal Women Be Encouraged to Take Calcium?
A systematic review of randomized, controlled trials of calcium supplementation found only small non-progressive increases in bone mineral density. This supports the clinical conclusion that supplementation alone is insufficient to prevent fracture risk.
-
Association of Coffee Consumption with Total and Cause-specific Mortality
Regular consumption of both caffeinated and decaffeinated coffee were found to be inversely associated with risk of total mortality and mortality attributed to cardiovascular disease and neurologic diseases.
-
High Blood Pressure: How Low Should We Go? SPRINT and a New Meta-analysis
A recent meta-analysis supports the benefit of targeting lower blood pressure levels.
-
FDA Actions
The FDA has approved a new fixed-dose combination oral, once-daily pill to treat hepatitis C genotypes 1 and 4.
-
Time to Limit Proton Pump Inhibitors?
A new study suggests the commonly used drugs may be associated with chronic kidney disease.
-
Promising Treatment Not Widely Available
Among adults with recurrent or refractory Clostridium difficile infection, the use of frozen compared with fresh fecal microbiota transplantation did not result in worse proportion of clinical resolution of diarrhea.
-
New Recommendations for Bisphosphonate Therapy
For women who are not at high risk after 3-5 years of bisphosphonate therapy, a drug holiday of 2-3 years may be considered.